Oral GLP-1 Approaches Commercial Inflection by 2028 GLP-1 Weight Loss Drug Market Revenue Share, CAGR, and Primary Drivers by Route 2026 Subcutaneous injectable administration commands 81.7% GLP-1 market revenue share in 2026 as the weekly autoinjector format delivers clinical efficacy, dose consistency, and patient convenience superior to daily injectable alternatives
one receptor (GLP-1) , while Tirzepatide targets two (GLP-1 and GIP)
A similar cell-type specificity was observed for the developmental action of leptin on AgRP projections to the PVH
Jorgensen JO, Vahl N, Hansen TB, Thuesen L, Hagen C, Christiansen JS
To prevent such damage, Retatrutide should always be kept in dark, airtight vials or stored in secondary containers that block UV exposure